COMPANION-002 (CTX-009-002)

Biliary Tract Cancer (BTC)

A Phase 2/3 study in adults with unresectable, advanced, metastatic or recurrent biliary tract cancer who have received one prior systemic chemotherapy regimen. This randomized study assesses the efficacy and safety of CTX-009 in combination with paclitaxel versus paclitaxel alone as a second-line therapy. The primary outcome is Overall Response Rate (ORR).

COMPANION-003 (CTX-009-003)

Colorectal Cancer

A Phase 2 study enrolling patients with metastatic colorectal cancer who have received two or three prior systemic chemotherapy regimens. This study assesses the efficacy and safety of CTX-009. The primary outcome is ORR (Overall Response Rate).

CTX-471 + KEYTRUDA® (pembrolizumab)

Solid Tumors

A Phase 1b arm enrolling patients who have metastatic or locally advanced non-small cell lung cancer, melanoma, small cell lung cancer, mesothelioma, and head and neck cancer who have progressed after treatment with a checkpoint inhibitor. Patients enrolled in the study are treated with a combination of CTX-471 + KEYTRUDA® (pembrolizumab) with the goal of restoring response.